Supported by an $86 Million Round, First Bio-Artificial Liver Moves Toward Pivotal Trials
November 9, 2012 - (MEDCITY News) - "Vital Therapies says it has the world’s first cell-based, bio-artificial liver designed to stabilize liver funnction in patients with life-threatening acute liver failure, and it’s headed for pivotal trials. Called Elad, the device has survived two companies that went bankrupt after spending $65 million developing it, according to Forbes." Read Full Article
